如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年6月18日 | 2,101,831,773 | | 16,657,052 ...

Core Viewpoint - The launch of Luwo Meitini tablets marks a significant advancement in the treatment of rare diseases in China, specifically targeting LCH and NF1, providing new therapeutic options for patients [1][2][3]. Group 1: Product Overview - Luwo Meitini tablets are the first and only targeted drug approved in China for both adult LCH and NF1 in children aged 2 and above [1]. - The drug is an innovative small molecule developed by Fosun Pharma, selectively inhibiting MEK1/2 protein activity to block the abnormal activation of the MAPK signaling pathway, thereby suppressing tumor cell proliferation and inducing apoptosis [2]. Group 2: Clinical Data and Efficacy - Clinical trial data shows a median follow-up time of 15.1 months, with a best objective response rate (ORR) of 60.5% and a median time to response (TTR) of 4.7 months, indicating effective and controllable safety [2]. - NF1 is a rare autosomal dominant genetic disorder, with a significant disease burden that can lead to pain, mobility issues, and disfigurement, necessitating the development of targeted therapies [2]. Group 3: Future Prospects - In addition to the current indications, Luwo Meitini is undergoing clinical trials for low-grade gliomas, extracranial arteriovenous malformations, and pediatric LCH, with the potential to expand its application to more disease areas [4].

重要内容提示（简称同正文） ● 截 至 2025 年 6 月 16 日 收 市 ， 控 股 股 东 复 星 高 科 技 持 有 本 公 司 961,424,455 股股份（其中：A 股 889,890,955 股、H 股 71,533,500 股），约占 截至当日收市本公司股份总数的 36.00%。本次质押及解除质押后，复星高科技 质押本公司股份数量余额为 685,300,000 股（均为 A 股），约占截至当日收市本 公司股份总数的 25.66%。 ● 截至 2025 年 6 月 16 日收市，控股股东复星高科技及其一致行动人（即 复星高科技董监高、复星国际有限公司及其董高<包括本公司实际控制人>，下同） 合计持有本公司967,812,180股股份（其中：A股890,278,680股、H股77,533,500 股），约占截至当日收市本公司股份总数的 36.24%。本次质押及解除质押后， 复星高科技及其一致行动人质押本公司股份数量余额为 685,300,000 股（均为 A 股），约占复星高科技及其一致行动人所持有本公司股份数的 70.81%。 上海复星医药（集团）股份有限公司（以下简称"本公司"）于 202 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | | | --- | --- | --- | --- | | 表格類別： 呈交日期： | 股票 2025年6月18日 | 狀態： | 新提交 | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： | 新提交 | | --- | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | | 呈交日期： | 2025年6月18日 | | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行股份或庫存股份變 ...

Investment Highlights - Financial performance shows commercial expansion and profit improvement, with 2024 sales revenue for 17 commercialized innovative drug companies reaching 91.3 billion yuan, a year-on-year growth of 35% [4][25] - R&D investment for 32 sample innovative drug companies is projected to be 67.2 billion yuan in 2024, reflecting a year-on-year increase of 7.23%, indicating a sustained trend of local innovation investment [4][13] - The sales expense ratio and R&D expense ratio for 22 sample innovative drug companies have been continuously declining from 2021 to 2024, which is expected to drive profit improvement for companies like BeiGene and Innovent [4][15] MNC Strategies - The report highlights the prominent "Chinaization" of IO+ADC strategies, with multinational corporations (MNCs) having strong first-generation IO pipeline layouts, but second-generation IO has not seen significant breakthroughs [4][27] - MNCs are increasingly relying on local innovative drugs as key pipeline assets, with many future potential products being sourced from Chinese companies [4][30] - MNCs are well-capitalized, with ample cash flow supporting the continued enrichment of their pipelines, particularly in the context of the evolving IO+ADC landscape [4][39] Domestic Market Dynamics - The report emphasizes the global innovation and valuation reshaping of Chinese drugs, driven by supportive domestic policies and increasing international competitiveness [4][45] - The value of BD transactions continues to validate the competitiveness of Chinese innovative drugs, with 2024 projected BD transaction income reaching 5.7 billion USD, accounting for 20% of global cooperation authorization total upfront payments [4][45][47] - The commercialization of major products is accelerating, with a rich NDA reserve expected to drive further growth in domestic commercialization [4][50]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年6 月1 7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 股東部分股份質押及解除質押的公告》，僅供參閱。 证券代码：60019 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-104 上海复星医药（集团）股份有限公司 关于股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ● 截 至 2025 年 6 月 16 日 收 市 ， 控 股 股 东 复 星 高 科 技 持 有 本 公 司 截至当日收市本公司股份总数的 36.00%。本次质押及解除质押后，复星高科技 质押本公司股份数量余额为 685,300,000 股（均为 A 股），约占截至当日收市本 公司股份总数的 25.66%。 ● 截至 2025 年 6 月 16 日收市，控股股东复星高科技及其一致行动人（即 复星高科技董监高、复星国际有限公司及其董高 <包括本公司实际控制人> ，下同） 合计持有本公司 967,812,180 股股份（其中：A 股 890,278,680 股、H 股 77,533,500 股），约占截至当日收市本公司股份总数的 36.24%。本次质押及解除质押后， 复星高科技及其一致行动人质押本公司股份数量余额 ...

Core Viewpoint - Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical have formed a strategic partnership to develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy, aimed at enhancing cancer treatment efficacy while minimizing toxicity [1][2][3] Company Overview - Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader with over 120 years of experience, focusing on innovative drug development and the production of generics and biologics [6] - Shanghai Fosun Pharmaceutical, founded in 1994, is a leading innovation-driven global healthcare company with a strong presence in pharmaceuticals and healthcare services, actively implementing its "4IN" strategy [9][10] Partnership Details - The agreement allows Fosun Pharma exclusive rights to develop, manufacture, and commercialize TEV-56278 in specific regions, while Teva retains rights in the rest of the world, facilitating global data generation [2][8] - This collaboration aims to leverage both companies' strengths, combining Teva's innovative drug development capabilities with Fosun Pharma's oncology expertise and market access in China [4][8] Product Information - TEV-56278 is designed to selectively deliver IL-2 to PD-1+ T cells, enhancing anti-tumor activity and reducing systemic toxicities, and is currently in Phase 1 trials for various cancers [5][8] - Preclinical data indicates that TEV-56278 may lead to tumor regression and improved T-cell responses, showcasing its potential as a novel cancer immunotherapy [5][8]

Core Viewpoint - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a shareholder holding more than 5% of the shares in Shanhe Pharmaceutical (300452), plans to reduce its holdings by up to 6.978 million shares, representing no more than 3% of the total share capital, between March 18, 2025, and June 15, 2025 [1] Summary by Relevant Sections - **Share Reduction Plan** - The reduction plan was completed on June 15, 2025, with an average reduction price of 12.54 yuan per share [1] - A total of 2.2828 million shares were reduced, accounting for 0.98% of the total shares [1] - **Post-Reduction Holdings** - After the reduction, Fosun Pharmaceutical holds 21.6453 million shares, which is 9.23% of the total share capital [1] - **Compliance and Business Operations** - The reduction plan complies with relevant laws and regulations, and the company's production and operations remain normal, with no change in control [1]